Vimarsana
Biggest News Aggregation in the World

Page 4 - Mina Sooch News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mina Sooch. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mina Sooch Today - Breaking & Trending Today

Ocuphire Announces Appointment of Jay S. Pepose, M.D., - Vimarsana News

Ocuphire Announces Appointment of Jay S. Pepose, M.D.,

Dr. Pepose is Recognized as an Esteemed Key Opinion Leader in Ophthalmology with Nearly 40 Years of Experience as a Leading Clinical Researcher and...

Ocuphire to Host Key Opinion Leader Event on Nyxol® as a Potential New Treatment Option for Reversing Pharmacologically Induced Mydriasis - Vimarsana News

Ocuphire to Host Key Opinion Leader Event on Nyxol® as a Potential New Treatment Option for Reversing Pharmacologically Induced Mydriasis

Highlights of Recent Positive Data from Nyxol's Phase 3 Registration Trial Roundtable Discussion by 3 KOLs with Unique Perspectives and Distinct Patient ...

Webcast examines post-pandemic M&A outlook - Vimarsana News

Webcast examines post-pandemic M&A outlook

Webcast examines post-pandemic M&A outlook Crain's Detroit Business Laura Marcero. The pandemic reshaped mergers and acquisitions in 2020, but it didn't halt them. Crain's will take a look back at the deals of 2020 and what to expect in 2021 in M&A trends in a webcast at 3:30 p.m. March 10. Senior reporter Dustin Walsh will host a series of conversations with guests including: Mina Sooch, CEO and co-founder, Ocuphire Pharma Inc. Greg Lehmkuhl, president and CEO, Lineage Logistics Rajesh U. Kothari, CFA managing director, Cascade Partners LLC Laura Marcero, managing director, Huron Consulting ...

Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbances - Vimarsana News

Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbances

Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbances January 05, 2021 07:00 ET | Source: Ocuphire Pharma Ocuphire Pharma Nyxol is in Late Stage Clinical Development for A New Ophthalmic Indication Top Line Data from LYNX-1 Expected 3Q2021 FARMINGTON HILLS, Mich., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced the initiation of patient recruit...